ID
36687
Description
Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient; ODM derived from: https://clinicaltrials.gov/show/NCT02375711 Brief Summary: The aim of this study is to investigate the role of immunosenescence in the HBV vaccination response in patients with renal insufficiency. Detailed Description: The risk of infection with hepatitis B during exposure to blood is high (30% against 1.8% for Hepatitis C Virus and HIV 1%) and dialysis patients are a population at risk. Vaccination against this virus, which is very effective in the general population (vaccine response: 90 to 95%), is highly recommended in dialysis patients. However, numerous studies have shown that HBV vaccination was less effective in patients with chronic renal disease than in the general population. The reasons for low vaccine response are poorly understood. However, recent data suggest that renal failure could induce accelerated immunosenescence. The aging of the immune system, or immunosenescence, is a complex and profound phenomenon of the immune system during life. The gradual reduction of the generation of naive T cells in the thymus is the major cause of immunosenescence. But this process is also associated with an accumulation of lymphocytes at the end of differentiation. In this context, the decrease in vaccine response and increased infections in renal insufficiency might be correlated, as in the elderly population, with the aging of the immune system. The aim of this study is to investigate the role of immunosenescence in the HBV vaccination response in patients with renal insufficiency. Vaccination against HBV is not performed for the purposes of the study, but due to the existing vaccine indication for the subject. Included patients receive vaccination as routine care according to the recommendations and the vaccination schedule recommended by the Health Authority.
Lien
https://clinicaltrials.gov/show/NCT02375711
Mots-clés
Versions (2)
- 15/01/2019 15/01/2019 -
- 01/06/2019 01/06/2019 -
Détendeur de droits
Centre Hospitalier Universitaire de Besancon
Téléchargé le
1 juin 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
HBV Vaccine in Chronic Renal Disease NCT02375711
Eligibility Criteria
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Hepatitis B status
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C3714514
- UMLS CUI [1,2]
- C0019163
- UMLS CUI [2,1]
- C0474232
- UMLS CUI [2,2]
- C0262926
Description
Psychosis
Type de données
boolean
Alias
- UMLS CUI [1]
- C0033975
Description
Immosuppresive Therapy
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0021079
- UMLS CUI [1,2]
- C0262926
Description
Infection or Neoplasms
Type de données
boolean
Alias
- UMLS CUI [1]
- C3714514
- UMLS CUI [2]
- C0006826
Similar models
Eligibility Criteria
- StudyEvent: Eligibility
C0474232 (UMLS CUI [1,2])
C0373595 (UMLS CUI [1,2])
C0474232 (UMLS CUI [1,2])
C0205160 (UMLS CUI [1,2])
C1285529 (UMLS CUI [1,2])
C2603343 (UMLS CUI [1,3])
C2347858 (UMLS CUI [1,2])
C2347026 (UMLS CUI [1,3])
C0035168 (UMLS CUI [1,4])
C0019163 (UMLS CUI [1,2])
C0474232 (UMLS CUI [2,1])
C0262926 (UMLS CUI [2,2])
C0262926 (UMLS CUI [1,2])
C0006826 (UMLS CUI [2])